[1] |
World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
|
[2] |
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
|
[3] |
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
|
[4] |
Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J, 2018,51(5). pii: 1800544. doi: 10.1183/13993003.00544-2018.
|
[5] |
Pontali O, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respiratory J, 2017,50(5). pii: 1701462. doi: 10.1183/13993003.01462-2017.
|
[6] |
Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol, 2007,22(1):39-43. doi: 10.1097/HCO.0b013e32801129eb.
|
[7] |
Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, et al. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. Int J Tuberc Lung Dis, 2018. doi: 10.5588/ijtld.18.0423.
|
[8] |
Zhao Y, Fox T, Manning K, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: A retrospective cohort study. Clin Infect Dis, 2019,68(9):1522-1529. doi: 10.1093/cid/ciy727.
|
[9] |
Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med, 2019,380(13):1201-1213. doi: 10.1056/NEJMoa1811867.
|
[10] |
Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med, 2020,382(10):893-902. doi: 10.1056/NEJMoa1901814.
|
[11] |
World Health Organization. Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Geneva: World Health Organization. 2017.
|
[12] |
Postema PG, Wilde AA. The measurement of the QT interval. Curr Opin Cardiol, 2014,10(3):287-287. doi: 10.2174/1573403x10666140514103612.
|
[13] |
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott), 2016,149(3):139-152. doi: 10.1177/1715163516641136.
|
[14] |
Hincapie-Castillo JM, Staley B, Henriksen C, et al. Development of a predictive model for drug-associated QT prolongation in the inpatient setting using electronic health record data. Am J Health Syst Pharm, 2019,76(14):1059-1070. doi: 10.1093/ajhp/zxz100.
|
[15] |
Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation, 1991,84(3):1136-1144. doi: 10.1161/01.cir.84.3.1136.
|
[16] |
Sharma ND, Rosman HS, Padhi ID, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol, 1998,81(2):238-240. doi: 10.1016/s0002-9149(97)00888-6.
|
[17] |
Pratt CM, Singh SN, Al-Khalidi HR, et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol, 2004,43(7):1211-1216. doi: 10.1016/j.jacc.2003.10.057.
|
[18] |
Singh SN, Al-Khalidi HR, et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol, 2004,43(7):1211-1216. doi: 10.1016/j.jacc.2003.10.057.
|
[19] |
Harausz E, Cox H, Rich M, et al. QTc prolongation and treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2015,19(4):385-391. doi: 10.5588/ijtld.14.0335.
|
[20] |
Altin T, Ozcan O, Turhan S, et al. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Canadian J Cardiol, 2007,23(11):907-908. doi: 10.1016/s0828-282x(07)70850-4.
|
[21] |
Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005,307(5707):223-237. doi: 10.1126/science.1106753.
|
[22] |
李凤丽, 阚晓红, 李琦, 等. MDR-TB患者采用不同化疗方案所致药物不良反应及治疗转归研究. 中国防痨杂志, 2018,40(8):805-809. doi: 10.3969/j.issn.1000-6621.2018.08.006.
|
[23] |
Yoon HY, Jo KW, Nam GB, et al. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. Int J Tuberc Lung Dis, 2017,21(9):996-1001. doi: 10.5588/ijtld.17.0174.
|
[24] |
Gueta I, Klempfner R, Markovits N, et al. Clinically significant incidental QTc prolongation is subject to within-individual variability. Ann Noninvasive Electrocardiol, 2020,25(2):e12699. doi: 10.1111/anec.12699.
|
[25] |
Olayanju O, Esmail A, Limberis J, et al. A Regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J, 2020,55(1). pii:1901181. doi: 10.1183/13993003.01181-2019.
|
[26] |
Trinkley KE, Page RL 2nd, Lien H, et al. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin, 2013,29(12):1719-1726. doi: 10.1185/03007995.2013.840568.
|